<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963272</url>
  </required_header>
  <id_info>
    <org_study_id>9734</org_study_id>
    <nct_id>NCT02963272</nct_id>
  </id_info>
  <brief_title>ST2 for the Management of Heart Failure - STADE-HF</brief_title>
  <acronym>STADE-HF</acronym>
  <official_title>Interest of ST2 to Diagnosis and Management of Patients With Heart Failure (HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is a severe disease, burdened with a poor prognosis (30% mortality at 2&#xD;
      years, 30% of rehospitalization within 1 month). It is also a major cause of health burden&#xD;
      representing between 1.5 and 2 billions euros per year in France. Approximately 75% of these&#xD;
      costs are due to hospitalization.&#xD;
&#xD;
      Besides physical examination and echocardiography, biology may help refine the diagnosis, but&#xD;
      also could provide powerful prognostic parameters.&#xD;
&#xD;
      This study aims to assess the value of ST2 in the management of patients admitted for HF to&#xD;
      reduce readmission at one month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale:&#xD;
&#xD;
      Heart failure (HF) is a severe disease, burdened with a poor prognosis (30% mortality at 2&#xD;
      years, 30% of rehospitalization within 1 month). It is also a major cause of health burden&#xD;
      representing between 1.5 and 2 billions euros per year in France. Approximately 75% of these&#xD;
      costs are due to hospitalization.&#xD;
&#xD;
      Besides physical examination and echocardiography, biology may help refine the diagnosis, but&#xD;
      also could provide powerful prognostic parameters. The natriuretic peptides are already&#xD;
      available and widely used to this purpose. Other biomarkers such as fibrosis markers are&#xD;
      promising. In a recently published preliminary work of a cohort of 180 cardiac patients, ST2&#xD;
      is proving to be a powerful prognostic biomarker.&#xD;
&#xD;
      This study aims to assess the value of ST2 in the management of patients admitted for HF to&#xD;
      reduce readmission at one month.&#xD;
&#xD;
      Primary and secondary endpoints:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      - Interest of ST2 to decrease rehospitalization at one month in patients admitted for HF in&#xD;
      the cardiology department and / or Internal Medicine.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        -  economic evaluation&#xD;
&#xD;
        -  Clinical Target: mortality, stay at hospital duration&#xD;
&#xD;
        -  Impact on biological markers of HF, renal function Population: Any adult being&#xD;
           hospitalized for any type of HF. A total of 300 patients will be over a period of 36&#xD;
           months, divided into 2 arms.&#xD;
&#xD;
      Methods: interventional, randomized, opened: the two strategies &quot;ST2 available&quot; versus &quot;ST2&#xD;
      not available&quot; will be compared The duration of patient participation is 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2017</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 26, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>1 month</time_frame>
    <description>The frequence of the rehospitalization of the patient according to the treatment received</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Compare the hospitalization cost at 1 month and the cost of biological diagnostic strategies (NT-proBNP with or without ST2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>measure of mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of HF Assay</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Measure of biological marker ST2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stay at hospital duration</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Evaluation of duration of hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of the renal function assay</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Measure of biological marker of renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for heart failure</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Rehospitalization rate for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for all causes</measure>
    <time_frame>1 month and 1 year</time_frame>
    <description>Rehospitalization rate for all causes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diastolic Heart Failure</condition>
  <condition>Systolic Heart Failure Stage C</condition>
  <arm_group>
    <arm_group_label>Conventional strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional strategy to manage the patients with HF, following the international guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST2-guided strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Management of patients follow the international guidelines but are also guided by the ST2, to adapt the drugs indicated in patients with HF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional strategy</intervention_name>
    <description>Conventional strategy to manage the patients with HF, following the international guidelines.</description>
    <arm_group_label>Conventional strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ST2-guided strategy</intervention_name>
    <description>patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology</description>
    <arm_group_label>ST2-guided strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart failure hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other study&#xD;
&#xD;
          -  Pregnancy, feeding&#xD;
&#xD;
          -  Refusal&#xD;
&#xD;
          -  Not possible to perform information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßois ROUBILLE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Regional Hospital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>ST2</keyword>
  <keyword>fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

